Skip to main content

Table 1 Demographic and clinical characteristics of nine patients treated with rituximab

From: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

Age (years) (mean (SD)) 40.9 (11.1)
(median (range)) 41.5 (21.0-55.0)
Disease duration (months) (mean (SD)) 49.0 (73.1)
(median (range)) 24.0 (12-240)
Female (number,%) 8 (88.9)
Male (number,%) 1 (11.1)
ANA positivity (number,%) 9 (100)
Anti-Scl70 positivity (number,%) 6 (66.7)
Follow-up (months)(mean (SD)) 16.7 (12.6)
(median (range)) 12 (6-36)
  1. The values are indicated as the mean (SD), median (range) or percentage. ANA, antinuclear antibodies; SD, standard deviation.